China became a net exporter of innovative treatments for the first time in the first half of the year, but with more ‘out-licensing’ agreements come more cancellations
With ever tighter profit margins in the domestic market, China’s innovative drug developers are increasingly partnering with foreign companies to pitch their products overseas. But while this route of “out-licensing” drugs is lucrative, it can also be precarious, with multiple contracts terminated this year alone…….
This article has a total of 2001 words. Continue reading after subscribing.